---
title: "CERO THERAPEUTICS HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266617834.md"
datetime: "2025-11-19T21:12:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266617834.md)
  - [en](https://longbridge.com/en/news/266617834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266617834.md)
generator: "portal-rs"
---

# CERO THERAPEUTICS HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -9.1.

EBIT: As of FY2025 Q3, the actual value is USD -4.369 M.

### Segment Revenue

-   The company has not recognized any revenue from any sources, including product sales, and does not expect to generate any revenue from the sale of products in the foreseeable future.

### Operational Metrics

-   **Research and Development Expenses**: R&D expenses were $2,386,244 for the three months ended September 30, 2025, compared to $1,774,210 for the same period in 2024, reflecting an increase of $612,034 or 34.5%.
-   **General and Administrative Expenses**: General and administrative expenses were $1,976,335 for the three months ended September 30, 2025, compared to $2,628,028 for the same period in 2024, reflecting a decrease of $651,693 or 24.8%.
-   **Net Loss**: Net loss for the three months ended September 30, 2025 was $4,856,395, compared to $4,227,967 for the same period in 2024, reflecting an increase of $628,428 or 14.9%.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was $12,273,817, compared to $11,375,873 for the same period in 2024, reflecting an increase of $897,944.
-   **Net Cash Provided by Investing Activities**: Net cash provided by investing activities for the nine months ended September 30, 2025 was $500,000, compared to $0 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: Net cash provided by financing activities for the nine months ended September 30, 2025 was $10,468,829, compared to $12,240,682 for the same period in 2024, reflecting a decrease of $1,771,853.

### Unique Metrics

-   **Deemed Dividends**: During the nine months ended September 30, 2025, the company recorded deemed dividends of $31,614,429 related to preferred stock conversions and warrant adjustments.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to substantially increase its R&D expenses for the foreseeable future as it continues the development of its product candidates through clinical development.
-   **Non-Core Business**: The company has arranged two equity lines of credit, one providing for the sale of up to 25,000,000 newly issued shares of Common Stock and the other providing for the purchase of up to $17.5 million of Common Stock on the satisfaction of certain conditions.

### Priority

-   The company anticipates that substantial additional funding will be needed in connection with its continuing operations, and it is actively seeking additional financing to achieve its business objectives.

### Related Stocks

- [CEROW.US](https://longbridge.com/en/quote/CEROW.US.md)

## Related News & Research

- [Inside Coca-Cola’s secretive innovation labs: How the beverage giant wants to automate dirty soda and refreshers](https://longbridge.com/en/news/296681725.md)
- [Southern Copper (NYSE:SCCO) Shares Up 8.3%  - Still a Buy?](https://longbridge.com/en/news/296638179.md)
- [Bank of America Corp DE Acquires 173,486 Shares of Trustmark Corporation $TRMK](https://longbridge.com/en/news/296675221.md)
- [Bank of America Corp DE Raises Holdings in McGrath RentCorp $MGRC](https://longbridge.com/en/news/296675165.md)
- [JPMorgan Chase lifts DBV Technologies stake to 14.29%](https://longbridge.com/en/news/296634235.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**